MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG
BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...
The market is suffering from a 'three-body problem,' says BTIG's Jonathan Krinsky
Jonathan Krinsky, chief market technician at BTIG, joins CNBC's 'The Exchange to discuss his outlook on stocks for 2025, what ...
24/7 Wall St. on MSN2d
Large-Cap Value Stocks Could Rule in 2025: 4 High-Yield Dividend Winners
Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they will ...
bovnews2d
BTIG Research Just Downgraded Fiverr International Ltd (FVRR) Stock—What Does This Mean for Investors?
BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...
Stock rally faces resistance: BTIG's Krinsky
The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...
Traders Magazine9y
BTIG Expands Transition Management, Hires Howell to Boost Business
BTIG is growing its transition management business and hired a senior executive to help boost business. The firm has hired Daniel Howell as a director who will be based in New York. His job is ...
bovnews1d
Beyond Air Inc (XAIR) Stock Settles at $0.41: What’s Contributing to This Price Point?
BTIG Research has recently reduced Beyond Air Inc (XAIR) stock to Neutral rating, as announced on June 25, 2024, according to Finviz. Earlier, on July 28, 2023, Piper Sandler had initiated the stock ...
Here are some of BTIG's top picks for the first half of 2025
BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...
Boston Scientific price target raised to $101 from $97 at BTIG
BTIG analyst Marie Thibault raised the firm’s price target on Boston Scientific (BSX) to $101 from $97 and keeps a Buy rating ...
BTIG Sticks to Their Buy Rating for Globus Medical (GMED)
In a report released today, Ryan Zimmerman from BTIG reiterated a Buy rating on Globus Medical (GMED – Research Report), with a price target of ...
Investing10d
BTIG sees a risk for 'a bigger January decline' in S&P 500
According to a BTIG strategist, the rally in the index was rejected from the previous support trendline and even though there are still four days left for the Santa Claus rally to deliver gains, there ...